Dapagliflozine et insuline pour le contrôle de la glycémie chez les patients diabétiques de type 2 hospitalisés

This clinical trial aims to investigate the effectiveness and safety of a diabetes medication called Dapagliflozin in managing blood sugar levels for hospitalized patients with Type 2 Diabetes. The standard care for these patients typically involves multiple insulin injections throughout the day. Dapagliflozin, which belongs to a class of drugs known as Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors, has shown promise in reducing cardiovascular mortality and improving kidney outcomes. This study hopes to provide valuable information on how well Dapagliflozin can control blood sugar levels and prevent complications in hospitalized patients with Type 2 Diabetes. During the trial, participants will be divided into two groups. One group will receive Dapagliflozin in addition to their regular insulin regimen, while the other group will continue with their insulin regimen only. Blood sugar levels will be measured four times a day: before breakfast, lunch, and dinner, and at night. The primary outcome of the study is to determine if the addition of Dapagliflozin results in similar blood sugar control compared to insulin alone, without increasing the risk of complications such as low blood sugar (hypoglycemia). The study will last for 12 days, covering the first 7 days of therapy in the hospital and 5 days post-discharge.